Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Apr;7(1):41-8.
doi: 10.1007/s11882-007-0029-8.

Sulfonamide allergy and cross-reactivity

Affiliations
Review

Sulfonamide allergy and cross-reactivity

Carolyn C Brackett. Curr Allergy Asthma Rep. 2007 Apr.

Abstract

Concerns about cross-allergenicity between sulfonamide antibiotics and nonantibiotic sulfonamide-containing drugs continue to complicate pharmacotherapy. Several elegant investigations have demonstrated unequivocal lack of interaction between the sulfonamide group and either cellular or humoral immunity. The immunologic determinant of type I immunologic responses to sulfonamide antibiotics is the N1 heterocyclic ring, and nonantibiotic sulfonamides lack this structural feature. Many non-type I hypersensitivity responses to sulfonamide antibiotics are attributable to reactive metabolites that cause either direct cytotoxicity or humoral or cellular responses. Metabolite formation is stereospecific to the N4 amino nitrogen of the sulfonamide antibiotics, a structure not found on any nonantibiotic sulfonamide drugs. Cellular immune responses to sulfonamide antibiotics are responsible for many non-immunoglobulin E-mediated dermatologic reactions; however, the stereospecificity of T-cell response renders cross-reactivity between sulfonamide antibiotics and nonantibiotics highly unlikely. Apparent cross-reactivity responses to sulfonamide-containing drugs likely represent multiple concurrent, rather than linked, drug hypersensitivities.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Br J Clin Pharmacol. 2003 Feb;55(2):158-65 - PubMed
    1. Br J Dermatol. 2000 Feb;142(2):253-8 - PubMed
    1. Allergy. 1999;54 Suppl 58:28-32 - PubMed
    1. J Allergy Clin Immunol. 1987 Oct;80(4):538-41 - PubMed
    1. Curr Opin Allergy Clin Immunol. 2003 Aug;3(4):255-60 - PubMed

LinkOut - more resources